Orhan Efe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Orhan Efe has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
Anushya Jeyabalan
Division of Nephrology, Massachusetts General Hospital , Boston, MA
5 shared publicationsAyman Al Jurdi
Division of Nephrology, Mass General Brigham Department of Medicine Boston, MA
4 shared publications- Ayman Al Jurdi
Department of Medicine, Nephrology Division, Massachusetts General Hospital, Harvard Medical School, Boston, MA
4 shared publications Gabriel Sauvage
Division of Nephrology, Mass General Brigham Department of Medicine Boston, MA
4 shared publicationsJohn L. Niles
Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts
4 shared publicationsKaren Laliberte
Vasculitis and Glomerulonephritis Center, Massachusetts General Hospital; Boston , MA
4 shared publications
Latest Publications
- 14 August 2026
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 39 (7) , 1411-1419
Anti-PLA2R antibody levels are associated with thromboembolism risk in individuals with membranous nephropathy and hypoalbuminemia
Background: Studies to evaluate markers of thrombotic risk in individuals with high-risk membranous nephropathy (MN) are needed. We hypothesized that high anti-phospholipase A2 receptor (PLA2R) titers at the time of severe hypoalbuminemia, reflecting ongoing immunologic disease activity, may be associated with a higher risk of thrombotic complications. Methods: We conducted a multicenter retrospective cohort study of individuals with membranous nephropathy and serum albumin <2.5 g/dL and evaluated risk factors for first thrombotic events. Results: Sixty-seven individuals met the inclusion criteria. Median serum creatinine was 1.2 mg/dL (Interquartile range [IQR] 0.9–1.6), median urine protein-to-creatinine ratio (UPCR) was 11.9 g/g (IQR 8.5–16.5), and median nadir serum albumin level was 1.9 g/dL (IQR 1.6–2.2). Twenty-four individuals (36%) received no thromboprophylaxis, 20 (30%) received prophylaxis with only antiplatelets, and 23 (34%) received anticoagulation prophylaxis. Thrombotic events occurred in 11 individuals (16%) with incidence rates of 0.11, 0.10, and 0.02 per person-year in the no prophylaxis, antiplatelet, and anticoagulation groups, respectively. In individuals with anti-PLA2R antibody-positive MN who did not receive anticoagulation thromboprophylaxis, higher anti-PLA2R antibody levels were associated with a higher risk of developing thrombotic complications (adjusted Hazard Ratio [HR] = 1.51 per 10 RU/mL increase in PLA2R, 95% Confidence Interval [CI]: 1.10–2.09, P = .012) after adjusting for serum albumin nadir and age. Conclusions: Higher anti-PLA2R antibody levels at the time of hypoalbuminemia are associated with a higher risk of thrombotic complications in individuals with anti-PLA2R-positive MN.
- 14 August 2026
- Published by Oxford University Press (OUP) in Journal Of Nephrology
- Vol. 39 (7) , 1411-1419
Anti-PLA2R antibody levels are associated with thromboembolism risk in individuals with membranous nephropathy and hypoalbuminemia
Background: Studies to evaluate markers of thrombotic risk in individuals with high-risk membranous nephropathy (MN) are needed. We hypothesized that high anti-phospholipase A2 receptor (PLA2R) titers at the time of severe hypoalbuminemia, reflecting ongoing immunologic disease activity, may be associated with a higher risk of thrombotic complications. Methods: We conducted a multicenter retrospective cohort study of individuals with membranous nephropathy and serum albumin <2.5 g/dL and evaluated risk factors for first thrombotic events. Results: Sixty-seven individuals met the inclusion criteria. Median serum creatinine was 1.2 mg/dL (Interquartile range [IQR] 0.9–1.6), median urine protein-to-creatinine ratio (UPCR) was 11.9 g/g (IQR 8.5–16.5), and median nadir serum albumin level was 1.9 g/dL (IQR 1.6–2.2). Twenty-four individuals (36%) received no thromboprophylaxis, 20 (30%) received prophylaxis with only antiplatelets, and 23 (34%) received anticoagulation prophylaxis. Thrombotic events occurred in 11 individuals (16%) with incidence rates of 0.11, 0.10, and 0.02 per person-year in the no prophylaxis, antiplatelet, and anticoagulation groups, respectively. In individuals with anti-PLA2R antibody-positive MN who did not receive anticoagulation thromboprophylaxis, higher anti-PLA2R antibody levels were associated with a higher risk of developing thrombotic complications (adjusted Hazard Ratio [HR] = 1.51 per 10 RU/mL increase in PLA2R, 95% Confidence Interval [CI]: 1.10–2.09, P = .012) after adjusting for serum albumin nadir and age. Conclusions: Higher anti-PLA2R antibody levels at the time of hypoalbuminemia are associated with a higher risk of thrombotic complications in individuals with anti-PLA2R-positive MN.
- Open Access
- 11 May 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (6)
Long-term B-cell depletion with rituximab in relapsing, refractory and severe lupus nephritis: a retrospective case series
Background: B-cell depletion with anti-CD20 agents has been evaluated as part of induction immunosuppression (IS) in lupus nephritis (LN). Data on its long-term efficacy for maintenance of remission remains limited. Methods: Retrospective case series evaluating outcomes in patients with relapsing, refractory and severe LN at diagnosis who received rituximab (RTX)-induced continuous B-cell depletion for both induction and maintenance at Massachusetts General Hospital from 2008 to 2023. Results: A total of 26 patients with active LN were included. Eighty-eight percent (23/26) had class III/IV ± V on kidney biopsy; 12% (3/26) had pure class V LN. Median follow-up (from first to last RTX) was 32 months [interquartile range (IQR) 14–68]; median cumulative dose of RTX was 10 g (IQR 6–17). At RTX initiation, all patients received prednisone and oral IS with an intention to taper off oral agents in 12 months. Eighty-one percent (21/26) achieved at least partial remission. Median prednisone dose decreased from 30 to 5 mg/day at 6 months (P < .01). Fifty-eight percent (15/26) of patients at 12 months and 79% (11/14) at 24 months were on RTX monotherapy. Six renal relapses occurred in five patients with median time-to-first relapse of 43 months (range 24–142); all episodes but one were preceded by B-cell repopulation. Five patients developed end-stage kidney disease; all had creatinine >2 mg/dL at RTX initiation. Thirty-one percent (8/26) experienced severe infections requiring hospitalization. No deaths occurred. Conclusion: Long-term continuous B-cell depletion may be an effective treatment strategy in patients with LN who have failed prior IS or with severe disease at diagnosis. Future controlled studies are needed to further evaluate this approach as the backbone therapy in LN.
- 11 May 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (6)
Open AccessLong-term B-cell depletion with rituximab in relapsing, refractory and severe lupus nephritis: a retrospective case series
Background: B-cell depletion with anti-CD20 agents has been evaluated as part of induction immunosuppression (IS) in lupus nephritis (LN). Data on its long-term efficacy for maintenance of remission remains limited. Methods: Retrospective case series evaluating outcomes in patients with relapsing, refractory and severe LN at diagnosis who received rituximab (RTX)-induced continuous B-cell depletion for both induction and maintenance at Massachusetts General Hospital from 2008 to 2023. Results: A total of 26 patients with active LN were included. Eighty-eight percent (23/26) had class III/IV ± V on kidney biopsy; 12% (3/26) had pure class V LN. Median follow-up (from first to last RTX) was 32 months [interquartile range (IQR) 14–68]; median cumulative dose of RTX was 10 g (IQR 6–17). At RTX initiation, all patients received prednisone and oral IS with an intention to taper off oral agents in 12 months. Eighty-one percent (21/26) achieved at least partial remission. Median prednisone dose decreased from 30 to 5 mg/day at 6 months (P < .01). Fifty-eight percent (15/26) of patients at 12 months and 79% (11/14) at 24 months were on RTX monotherapy. Six renal relapses occurred in five patients with median time-to-first relapse of 43 months (range 24–142); all episodes but one were preceded by B-cell repopulation. Five patients developed end-stage kidney disease; all had creatinine >2 mg/dL at RTX initiation. Thirty-one percent (8/26) experienced severe infections requiring hospitalization. No deaths occurred. Conclusion: Long-term continuous B-cell depletion may be an effective treatment strategy in patients with LN who have failed prior IS or with severe disease at diagnosis. Future controlled studies are needed to further evaluate this approach as the backbone therapy in LN.
- Open Access
- 24 January 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (3)
Thrombotic microangiopathy after kidney transplantation: diagnosis and management strategies
Thrombotic microangiopathy (TMA) is a pathological condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and ischemic organ dysfunction due to microvascular endothelial damage and thrombosis. It affects ∼0.8%–14% of kidney transplant recipients, and may manifest as either a recurrent or de novo disease. While systemic manifestations are commonly anticipated, kidney-limited TMA can also occur and is not rare. Histopathologic examination of allograft biopsies shows morphologic features indicating endothelial injury, and repeated episodes of TMA may result in coexisting acute and chronic lesions within the same patient. In transplant recipients, multiple triggers contribute to endothelial damage, including ischemia-reperfusion injury, antibody-mediated rejection, immunosuppressive agents (calcineurin and mTOR inhibitors), and infections. The risk is particularly important in individuals with genetic variants that dysregulate the alternative complement pathway. In de novo TMA, environmental triggers and transplant-related stressors play a central role, whereas genetic predisposition is the primary factor in recurrent cases. Notably, these mechanisms often overlap and may act synergistically. Recurrent atypical hemolytic uremic syndrome can successfully be managed with terminal complement inhibitors, and prophylactic use of eculizumab in the peri-transplant period has significantly reduced recurrence rates. Management of de novo TMA begins with the identification and removal of precipitating factors. In cases where no clear trigger is found, or when the disease proves refractory to conventional therapy, terminal complement inhibition may be an effective therapeutic option. The prognosis of recurrent TMA has improved substantially with the advent of complement targeting therapies but research is still needed to optimize management strategies.
- 24 January 2026
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 19 (3)
Open AccessThrombotic microangiopathy after kidney transplantation: diagnosis and management strategies
Thrombotic microangiopathy (TMA) is a pathological condition characterized by microangiopathic hemolytic anemia, thrombocytopenia, and ischemic organ dysfunction due to microvascular endothelial damage and thrombosis. It affects ∼0.8%–14% of kidney transplant recipients, and may manifest as either a recurrent or de novo disease. While systemic manifestations are commonly anticipated, kidney-limited TMA can also occur and is not rare. Histopathologic examination of allograft biopsies shows morphologic features indicating endothelial injury, and repeated episodes of TMA may result in coexisting acute and chronic lesions within the same patient. In transplant recipients, multiple triggers contribute to endothelial damage, including ischemia-reperfusion injury, antibody-mediated rejection, immunosuppressive agents (calcineurin and mTOR inhibitors), and infections. The risk is particularly important in individuals with genetic variants that dysregulate the alternative complement pathway. In de novo TMA, environmental triggers and transplant-related stressors play a central role, whereas genetic predisposition is the primary factor in recurrent cases. Notably, these mechanisms often overlap and may act synergistically. Recurrent atypical hemolytic uremic syndrome can successfully be managed with terminal complement inhibitors, and prophylactic use of eculizumab in the peri-transplant period has significantly reduced recurrence rates. Management of de novo TMA begins with the identification and removal of precipitating factors. In cases where no clear trigger is found, or when the disease proves refractory to conventional therapy, terminal complement inhibition may be an effective therapeutic option. The prognosis of recurrent TMA has improved substantially with the advent of complement targeting therapies but research is still needed to optimize management strategies.
- 4 August 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (3) , 523-525
Should Nephrology Clinical Trials Account for Apolipoprotein L1 Gene Risk Status?
- 4 August 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (3) , 523-525
Should Nephrology Clinical Trials Account for Apolipoprotein L1 Gene Risk Status?
- 29 July 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (2) , 352-355
How I Treat Challenging Cases of Antibody-Mediated Glomerular Diseases
An abstract is unavailable. This article is available as a PDF only.
- 29 July 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 21 (2) , 352-355
How I Treat Challenging Cases of Antibody-Mediated Glomerular Diseases
An abstract is unavailable. This article is available as a PDF only.
- 12 June 2025
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 392 (22) , 2257-2265
Case 16-2025: A 34-Year-Old Man with a Nasopharyngeal Mass
- 12 June 2025
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 392 (22) , 2257-2265
Case 16-2025: A 34-Year-Old Man with a Nasopharyngeal Mass
- 19 February 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (4) , 588-590
IgG4-Related Kidney Disease
An abstract is unavailable. This article is available as a PDF only.
- 19 February 2025
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (4) , 588-590
IgG4-Related Kidney Disease
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 8 February 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (5) , 1441-1449
Persistent B Cell Depletion After Rituximab for Autoimmune and Glomerular Diseases: A Case Series
- 8 February 2025
- Published by Elsevier in Kidney International Reports
- Vol. 10 (5) , 1441-1449
Open AccessPersistent B Cell Depletion After Rituximab for Autoimmune and Glomerular Diseases: A Case Series
- Open Access
- 23 December 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (4) , 2303-2305
Protracted COVID-19 pneumonia in B-cell-depleted patients
- 23 December 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (4) , 2303-2305
Open AccessProtracted COVID-19 pneumonia in B-cell-depleted patients
- Open Access
- 30 November 2024
- Published by Elsevier in Kidney International Reports
- Vol. 10 (3) , 944-947
Combination Induction Immunosuppression With Rituximab, Cyclophosphamide, and Prednisone for Fibrillary Glomerulonephritis
- 30 November 2024
- Published by Elsevier in Kidney International Reports
- Vol. 10 (3) , 944-947
Open AccessCombination Induction Immunosuppression With Rituximab, Cyclophosphamide, and Prednisone for Fibrillary Glomerulonephritis